Camrelizumab+chemotherapy

Phase 2Small molecule

HHebei Medical University Fourth Hospital

Camrelizumab+chemotherapy is one of 46 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Gastric CancerActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastric CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

1 2

Medrol

Pfizer

Preclinical

1 3

MS Contin

Merck & Co.

Preclinical

1 4

Camrelizumab+chemotherapy

HHebei Medical University Fourth Hospital

Phase 2

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Active Comparator

Moderna

Preclinical

1 8

Chemotherapy Agents

Takeda

Preclinical

1 9

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 10

Rybelsus

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pancreatic Cancer

NCT06435260

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Suspended·SShanghai Minimally Invasive Surgery Center·Phase 1/2·NCT05101616·100 enrolled

Pancreatic Cancer1 trial

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06435260·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Camrelizumab+chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camrelizumab+chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camrelizumab+chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Medical University Fourth Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHebei Medical University Fourth Hospital

Camrelizumab+chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Gastric Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News